# Intabio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intabio

- Industry: Biotechnology
- Headquarters: Newark, US
- Website: www.intabio.com
- Total disclosed funding: $30M
- Latest round: Series B (Feb 6, 2020)
- Investors on record: 4

## About

Intabio, Inc. leverages iCIEF-MS technology to provide innovative mass spectrometry solutions aimed at precise molecular detection, enhancing research capabilities across pharmaceutical, clinical, and environmental sectors.Founded in 2015 and headquartered in Newark, US, Intabio, Inc. specializes in advanced mass spectrometry solutions. The company was acquired in January 2021 by AB Sciex LLC from a group of investors including Vertical Venture Partners and Northpond Ventures. The founder's history is not documented, and there have been no reported pivots or subsidiaries. The company has raised a total of USD 18.00 mn through its Series B funding round, led by Northpond Ventures, with a current valuation of USD 43.15 mn.Intabio, Inc. focuses on iCIEF-MS Technology providing advanced mass spectrometry solutions for precise molecular detection and quantitation. Their product lineup includes innovative LC-MS systems, tailored consumables, and standards that support sample analysis in pharmaceuticals, clinical diagnostics, environmental monitoring, and food safety. These offerings cater to diverse clients, including pharmaceutical companies, clinical labs, and regulatory agencies across North America, Europe, and Asia.Intabio, Inc. generates revenue through direct sales and partnerships, engaging in B2B transactions for mass spectrometry systems and consumables. Customized solutions and training programs complement their revenue model, with pricing reflecting the advanced capabilities of their flagship products. Their services include expert training and ongoing technical support, essential for maintaining client relationships and fostering business growth.Following the acquisition by AB Sciex LLC, Intabio, Inc. aims to innovate its product offerings and expand its market reach. The company is focused on developing new products tailored to enhance research and diagnostics capabilities, with specific plans for geographic expansion into Asia and Europe by early 2023. The recent funding from the Series B round will be utilized to enhance product development, support marketing strategies, and facilitate entry into these new markets.

## Funding rounds

- Series B, Feb 6, 2020, $18M — Vertical Venture Partners, Genoa Ventures, Northpond Ventures
- Series A, Oct 24, 2018, $9.2M — Vertical Venture Partners, Genoa Ventures, Northpond Ventures
- Seed, Sep 14, 2017, $3.2M — Vertical Venture Partners, Morgan Noble, Genoa Ventures

## Investors

- Vertical Venture Partners (https://capitalatlas.ai/funds/vertical-venture-partners) — Seed, Series A, Series B
- Morgan Noble (https://capitalatlas.ai/funds/morgan-noble) — Seed
- Genoa Ventures (https://capitalatlas.ai/funds/genoa-ventures) — Seed, Series A, Series B
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A, Series B